A Multiple Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Multiple Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2017
At a glance
- Drugs NN 9277 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 07 Nov 2017 Planned End Date changed from 18 Dec 2018 to 23 Dec 2018.
- 07 Nov 2017 Status changed from not yet recruiting to recruiting.
- 17 Oct 2017 New trial record